PATIENT OUTCOMES are becoming an important metric for new drugs, and long overdue. Gatekeeping of a successful medicine has shifted in recent years from the FDA to payers, and pharmacoeconomics, as the UK’s NICE committee has recently demonstrated in exclusion decisions for expensive drugs.
http://lnkd.in/dejJgi
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022